Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

1 Dec 2021

Abstract excerpt

Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34922619
DOI: 10.1186/s13148-021-01210-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancerPMID 34922619Read ↗

Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical valueSemantic proximity Read ↗

Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast CancerSemantic proximity Read ↗

The DNA methylation landscape of primary triple-negative breast cancerSemantic proximity Read ↗

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patientsSemantic proximity Read ↗

Targeting DNA Methylation for Treating Triple-Negative Breast CancerSemantic proximity Read ↗

Epigenetic Alterations in Triple-Negative Breast Cancer—The Critical Role of Extracellular MatrixSemantic proximity Read ↗

Predicting neoadjuvant treatment response in triple-negative breast cancer using machine learningSemantic proximity Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Development and validation of a novel 15‐CpG‐based signature for predicting prognosis in triple‐negative breast cancerSemantic proximity Read ↗

Regional methylome profiling reveals dynamic epigenetic heterogeneity and convergent hypomethylation of stem cell quiescence-associated genes in breast cancer following neoadjuvant chemotherapySemantic proximity Read ↗

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.